Publications by authors named "Guillermo Rossiter"

Claim this Profile
P
Phase 1b Study of Tovorafenib, Plozalizumab or Vedolizumab Plus Standard-of-Care Immune Checkpoint Inhibitors in Patients with Advanced Melanoma.
Ryan J Sullivan, Katy K Tsai, Anna C Pavlick, Elizabeth I Buchbinder, Sanjiv S Agarwala, Guillermo Rossiter

J Cancer· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vedolizumab for prevention of lower-GI acute GVHD in the Japanese subgroup analysis of the phase 3 GRAPHITE study.
Tatsunori Goto, Hiroshi Okamura, Takashi Ikeda, Yasuo Mori, Souichi Shiratori, Guillermo Rossiter

Int J Hematol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of intravenous vedolizumab treatment in Chinese patients with moderate-to-severe Crohn's disease.
Minhu Chen, Xiang Gao, Qian Cao, Guillermo Rossiter, Tadayuki Kitagawa

Clin Res Hepatol Gastroenterol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Practical considerations of promising zone design for interim sample size Re-estimation: An application to GRAPHITE for graft vs host disease.
Jingjing Chen, Yohei Takanami, Johan Jansson, Guillermo Rossiter

Contemp Clin Trials· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vedolizumab for the prevention of intestinal acute GVHD after allogeneic hematopoietic stem cell transplantation: a randomized phase 3 trial.
Yi-Bin Chen, Mohamad Mohty, Robert Zeiser, Takanori Teshima, Omer Jamy, Guillermo Rossiter

Nat Med· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics, Safety and Efficacy of Intravenous Vedolizumab in Paediatric Patients with Ulcerative Colitis or Crohn's Disease: Results from the Phase 2 HUBBLE Study.
Jeffrey S Hyams, Dan Turner, Stanley A Cohen, Erzsébet Szakos, Kinga Kowalska-Duplaga, Guillermo Rossiter

J Crohns Colitis· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mongersen (GED-0301) for Active Crohn's Disease: Results of a Phase 3 Study.
Bruce E Sands, Brian G Feagan, William J Sandborn, Stefan Schreiber, Laurent Peyrin-Biroulet, Guillermo Rossiter

Am J Gastroenterol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Mongersen (GED-0301) on Endoscopic and Clinical Outcomes in Patients With Active Crohn's Disease.
Brian G Feagan, Bruce E Sands, Guillermo Rossiter, Xiaobin Li, Keith Usiskin

Gastroenterology· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis